文献速递神经肿瘤功能神经外科

经蝶术后持续或复发库欣病的放射外科管理:基于25年经验的管理算法

Radiosurgical Management of Patients With Persistent or Recurrent Cushing Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience.
PubMed 文献 · Neurosurgery · 2020-01-01

该研究回顾性分析了1990至2015年38例经蝶术后持续或复发促肾上腺皮质激素(ACTH)分泌垂体腺瘤患者接受立体定向放射外科(SRS)的结局。中位随访76个月,双侧肾上腺切除(Adx)联合SRS组90%获良好结局,单纯SRS组72%获良好结局;1年和3年良好结局率Adx+SRS组更高,5年无差异。结论提示SRS有效,轻中度患者可单用SRS,重度患者应考虑Adx联合SRS或后续SRS。

要点

  • Adx联合SRS组90%获良好结局,单纯SRS组72%获良好结局。
  • 1年良好结局率Adx+SRS组100% vs 单纯SRS组33%(P<.001)。
  • 3年良好结局率Adx+SRS组100% vs 单纯SRS组62%(P<.01)。

核心结论

  • SRS对经蝶术后持续或复发CD有效。
  • 轻中度CD可安全单用SRS管理。
  • 重度CD应考虑Adx联合同期SRS或肿瘤生长时后期SRS。

研究设计与样本

  • 回顾性综述1990至2015年38例未接受过放疗的ACTH分泌垂体腺瘤患者接受SRS。
  • 良好结局定义为生化缓解和肿瘤生长控制。
  • 接受双侧肾上腺切除(Adx)的患者单独评估。

主要发现

  • 20例(53%)接受Adx联合SRS(中位边缘剂量25 Gy),18例(47%)单纯SRS(中位边缘剂量22.5 Gy)。
  • SRS后中位随访76个月。
  • Adx组18/20(90%)获良好结局,2例(10%)肿瘤生长需额外治疗。
  • 单纯SRS组13/18(72%)获良好结局(中位14个月,四分位距8-23),5例(28%)因持续高皮质醇血症(n=4)或高皮质醇血症合并肿瘤生长(n=1)需额外治疗。
  • 良好结局在Adx联合SRS组1年(100% vs 33%;P<.001)和3年(100% vs 62%;P<.01)更常见,5年无差异(88% vs 77%;P=.63)。

临床怎么用

  • 对经蝶术后持续或复发CD患者,可评估SRS作为治疗选择。
  • 轻中度CD患者可考虑单纯SRS。
  • 重度CD患者应考虑Adx联合同期SRS或肿瘤生长时后期SRS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with persistent or recurrent Cushing disease (CD) after prior transsphenoidal surgery require further treatment to reduce the disease's metabolic consequences. OBJECTIVE: To assess patient outcomes after stereotactic radiosurgery (SRS) for persistent or recurrent CD from adrenocorticotropin hormone (ACTH)-secreting pituitary adenomas and propose a management algorithm. METHODS: Retrospective review of 38 patients without prior radiation treatment having SRS for ACTH-secreting pituitary adenomas from 1990 to 2015. Favorable outcome was defined as biochemical remission and tumor growth control. Patients were evaluated separately if they underwent bilateral adrenalectomy (Adx). RESULTS: Twenty patients (53%) were treated with Adx and SRS (median margin dose, 25 Gy) and 18 patients (47%) received SRS alone (median margin dose, 22.5 Gy). Median follow-up after SRS was 76 mo. Of patients undergoing Adx, 18/20 (90%) had a favorable outcome. Two patients (10%) had tumor growth requiring additional treatment. A favorable outcome was achieved in 13/18 patients (72%) having SRS alone (median, 14 mo; interquartile range, 8-23). Five patients (28%) required additional treatment due to persistent hypercortisolemia (n = 4) or hypercortisolemia and tumor growth (n = 1). Favorable outcomes were more frequent in the Adx and SRS group at 1 yr (100% vs 33%; P < .001) and 3 yr (100% vs 62%; P < .01), but no different at 5 yr (88% vs 77%; P = .63). CONCLUSION: SRS was effective for patients with persistent or recurrent CD. Patients with mild to moderate CD can be safely managed with SRS alone; patients with severe CD should be considered for Adx with either concurrent SRS or SRS performed at a later date if tumor growth occurs.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Hughes JD, Young WF, Chang AY, et al. Radiosurgical Management of Patients With Persistent or Recurrent Cushing Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience. Neurosurgery. 2020. PMID: 31140563. doi:10.1093/neuros/nyz159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。